PUMA BIOTECHNOLOGY INC's ticker is PBYI and the CUSIP is 74587V107. A total of 83 filers reported holding PUMA BIOTECHNOLOGY INC in Q3 2022. The put-call ratio across all filers is 0.19 and the average weighting 0.0%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $395 | -99.2% | 150 | -99.1% | 0.00% | – |
| Q2 2023 | $51,935 | +4.6% | 16,214 | -4.3% | 0.00% | – |
| Q1 2023 | $49,666 | -32.9% | 16,941 | -2.8% | 0.00% | – |
| Q4 2022 | $74,000 | +76.2% | 17,430 | -0.3% | 0.00% | – |
| Q3 2022 | $42,000 | 0.0% | 17,482 | +16.7% | 0.00% | – |
| Q2 2022 | $42,000 | +27.3% | 14,980 | -1.8% | 0.00% | – |
| Q1 2022 | $33,000 | -32.7% | 15,260 | -2.0% | 0.00% | – |
| Q4 2021 | $49,000 | -75.0% | 15,571 | -46.7% | 0.00% | – |
| Q3 2021 | $196,000 | +46.3% | 29,219 | +100.4% | 0.00% | – |
| Q2 2021 | $134,000 | +5.5% | 14,577 | +11.6% | 0.00% | – |
| Q1 2021 | $127,000 | +2.4% | 13,060 | +7.6% | 0.00% | – |
| Q4 2020 | $124,000 | -15.6% | 12,140 | -16.3% | 0.00% | – |
| Q3 2020 | $147,000 | +36.1% | 14,510 | +40.1% | 0.00% | – |
| Q2 2020 | $108,000 | +35.0% | 10,355 | +8.5% | 0.00% | – |
| Q1 2020 | $80,000 | – | 9,540 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Athyrium Capital Management, LP | 1,792,114 | $4,713,260 | 4.15% |
| Eversept Partners, LP | 1,681,149 | $4,421,422 | 0.37% |
| Camber Capital Management LP | 4,235,000 | $11,138 | 0.37% |
| Kynam Capital Management, LP | 473,975 | $1,246,554 | 0.20% |
| GLOBEFLEX CAPITAL L P | 538,559 | $1,416,410 | 0.17% |
| Affinity Asset Advisors, LLC | 202,349 | $532,178 | 0.15% |
| GSA CAPITAL PARTNERS LLP | 279,629 | $735 | 0.06% |
| RICE HALL JAMES & ASSOCIATES, LLC | 363,666 | $956,442 | 0.06% |
| Patriot Financial Group Insurance Agency, LLC | 67,000 | $176,210 | 0.04% |
| ACADIAN ASSET MANAGEMENT LLC | 1,858,000 | $4,884 | 0.02% |